Florida International University
Edit Your Profile
FIU Discovery
Toggle navigation
Browse
Home
People
Organizations
Scholarly & Creative Works
Research Facilities
Support
International Journal of Radiation Oncology Biology Physics
Journal
Overview
Identifiers
View All
Overview
publication venue for
Tumor Treating Fields (TTFields) after Stereotactic Radiosurgery (SRS) for Brain Metastases from Non-Small Cell Lung Cancer (NSCLC BM): Final Results of The Phase 3 METIS Trial
. 123:278-293.
2026
Signal-Seeking P2R Trial of Proton or IMRT Dose Intensification in GBM: NRG-BN001
. 123:1204.
2025
Tumor Treating Fields (TTFields) after Stereotactic Radiosurgery (SRS) for Brain Metastases from Non-Small Cell Lung Cancer (NSCLC BM): Final Results of The Phase 3 METIS Trial
. 123:1196-1197.
2025
Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma
. 123:84-92.
2025
Evaluating Neurocognitive Improvement Following Stereotactic Radiosurgery and Whole Brain Radiation Therapy: A Pooled Analysis of Two Phase III Trials
. 123.
2025
Radiation Therapy Alone vs. Radiation Therapy Plus Radiofrequency Ablation/Vertebral Augmentation for Painful Spine Metastasis: A Randomized Controlled Trial
. 123.
2025
Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm Phase 2 Trial
. 122:957-967.
2025
Contrast-enhancing Lesions Induced by Central Nervous System-directed Intensity Modulated Proton Therapy: Distribution Patterns, Kinetics, Risk Factors, and Outcomes
. 122:621-630.
2025
Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Infradiaphragmatic Oligometastatic Disease : Disrupting the One-Size-Fits-All Paradigm
. 122:739-751.
2025
Temporal Evolution and Diagnostic Diversification of Patients Receiving Proton Therapy in the United States: A Ten-Year Trend Analysis (2012 to 2021) From the National Association for Proton Therapy
. 119:1069-1077.
2024
Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology ' s RTOG 0614
. 119:846-857.
2024
Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+Breast Cancer With Brain Metastases: NRG Oncology - KROG/ RTOG 1119 Phase 2 Randomized Trial
. 118:1391-1401.
2024
Commissioning Intracranial Stereotactic Radiosurgery for a Magnetic Resonance-Guided Radiation Therapy (MRgRT) System: MR-RT Localization and Dosimetric End-to-End Validation
. 118:512-524.
2024
Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole- Brain Radiation Therapy for Brain Metastases : Final Results of NRG Oncology CC001
. 117:571-580.
2023
Low-Dose Whole Brain Radiation Therapy for Alzheimer's Dementia: Results From a Pilot Trial in Humans
. 117:87-95.
2023
Deep Learning-Based Automatic Detection of Brain Metastases in Heterogenous Multi- Institutional Magnetic Resonance Imaging Sets: An Exploratory Analysis of NRG-CC001
. 114:529-536.
2022
Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors
. 114:60-74.
2022
Boosting the Abscopal Effect Using Immunogenic Biomaterials With Varying Radiation Therapy Field Sizes
. 112:475-486.
2022
Multi-Institutional Experience Of Proton Beam Radiotherapy For Patients With Craniopharyngiomas
. 108:e743-e744.
2020
High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539
. 106:790-799.
2020
Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer
. 104:325-333.
2019
Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420
. 103:878-886.
2019
Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases
. 101:845-853.
2018
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525
. 100:38-44.
2018
Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA)
. 99:812-816.
2017
Significant Dose Reduction to Central Neck Structures While Maintaining Locoregional Control in Patients with Advanced Head Neck Cancer Treated with Half-Beam-IMRT and AP Low Neck (HB-IMRT/AP) Radiotherapy Technique
. 99:e356.
2017
A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients
. 98:820-828.
2017
Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials
. 97:228-235.
2017
Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer
. 97:362-371.
2017
4-1BB Aptamer-Based Immunomodulation Enhances the Therapeutic Index of Radiation Therapy in Murine Tumor Models
. 96:458-461.
2016
Radiation-Induced Tumor Targeting of Immunomodulatory Aptamers Induces Abscopal Response and Tumor Control in Murine Models of Breast Cancer
. 96:s127.
2016
International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties
. 95:1102-1106.
2016
Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424
. 91:497-504.
2015
Real-Time Pretreatment Review Limits Unacceptable Deviations on a Cooperative Group Radiation Therapy Technique Trial: Quality Assurance Results of RTOG 0933
. 91:564-570.
2015
Memory Preservation With Conformal Avoidance of the Hippocampus During Whole-Brain Radiation Therapy for Patients With Brain Metastases: Primary Endpoint Results of RTOG 0933
. 87:1186.
2013
RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
. 86:880-884.
2013
A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320
. 85:1312-1318.
2013
RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients
. 85:1206-1211.
2013
Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors
. 85:348-354.
2013
A Unique Geographical Analysis of Lung Cancer Patients in the State of Utah
. 84:s572.
2012
Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors
. 83:E487-E493.
2012
EFFECT OF TUMOR SUBTYPE ON SURVIVAL AND THE GRADED PROGNOSTIC ASSESSMENT FOR PATIENTS WITH BREAST CANCER AND BRAIN METASTASES
. 82:2111-2117.
2012
A PHASE I TRIAL OF TIPIFARNIB WITH RADIATION THERAPY, WITH AND WITHOUT TEMOZOLOMIDE, FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
. 81:1422-1427.
2011
VALIDATION AND SIMPLIFICATION OF THE RADIATION THERAPY ONCOLOGY GROUP RECURSIVE PARTITIONING ANALYSIS CLASSIFICATION FOR GLIOBLASTOMA
. 81:623-630.
2011
Patient Setup Accuracy and Immobilization Errors during Lung, Spine, and Liver Stereotactic Body Radiation Therapy Delivery: Preliminary Experience using a Body Fix with Dual Vacuum Immobilization and a Robotic Couch
. 81:s61-s62.
2011
INTENSITY-MODULATED RADIOTHERAPY MIGHT INCREASE PNEUMONITIS RISK RELATIVE TO THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY IN PATIENTS RECEIVING COMBINED CHEMOTHERAPY AND RADIOTHERAPY: A MODELING STUDY OF DOSE DUMPING
. 80:893-899.
2011
ROLE OF ADJUVANT RADIOTHERAPY IN GRANULOSA CELL TUMORS OF THE OVARY
. 79:770-774.
2011
HIPPOCAMPAL-SPARING WHOLE-BRAIN RADIOTHERAPY: A "HOW-TO" TECHNIQUE USING HELICAL TOMOTHERAPY AND LINEAR ACCELERATOR-BASED INTENSITY-MODULATED RADIOTHERAPY
. 78:1244-1252.
2010
Determinants of Therapeutic Resistance in Glioblastomas: Lessons Learned from RTOG 0211 and Beyond
. 78:s257.
2010
ANGIOGENIC BLOCKADE AND RADIOTHERAPY IN HEPATOCELLULAR CARCINOMA
. 78:188-193.
2010
COGNITION AND QUALITY OF LIFE AFTER CHEMOTHERAPY PLUS RADIOTHERAPY (RT) VS. RT FOR PURE AND MIXED ANAPLASTIC OLIGODENDROGLIOMAS: RADIATION THERAPY ONCOLOGY GROUP TRIAL 9402
. 77:662-669.
2010
DIAGNOSIS-SPECIFIC PROGNOSTIC FACTORS, INDEXES, AND TREATMENT OUTCOMES FOR PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES: A MULTI-INSTITUTIONAL ANALYSIS OF 4,259 PATIENTS
. 77:655-661.
2010
AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY (ASTRO) AND AMERICAN COLLEGE OF RADIOLOGY (ACR) PRACTICE GUIDELINE FOR THE PERFORMANCE OF STEREOTACTIC BODY RADIATION THERAPY
. 76:326-332.
2010
Dosimetric Comparison of Stereotactic Body Radiotherapy for Early Stage Non-small Cell Lung Cancer with Intensity-modulated Proton Therapy and Helical Tomotherapy
. 75:s704.
2009
A PHASE II STUDY OF PRERADIOTHERAPY CHEMOTHERAPY FOLLOWED BY HYPERFRACTIONATED RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK MEDULLOBLASTOMA/PRIMITIVE NEUROECTODERMAL TUMOR: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (CCG 9931)
. 74:1006-1011.
2009
A COMPREHENSIVE ASSESSMENT BY TUMOR SITE OF PATIENT SETUP USING DAILY MVCT IMAGING FROM MORE THAN 3,800 HELICAL TOMOTHERAPY TREATMENTS
. 73:1260-1269.
2009
MOTEXAFIN GADOLINIUM COMBINED WITH PROMPT WHOLE BRAIN RADIOTHERAPY PROLONGS TIME TO NEUROLOGIC PROGRESSION IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH BRAIN METASTASES: RESULTS OF A PHASE III TRIAL
. 73:1069-1076.
2009
PHASE I THREE-DIMENSIONAL CONFORMAL RADIATION DOSE ESCALATION STUDY IN NEWLY DIAGNOSED GLIOBLASTOMA: RADIATION THERAPY ONCOLOGY GROUP TRIAL 98-03
. 73:699-708.
2009
DOSE COVERAGE BEYOND THE GROSS TUMOR VOLUME FOR VARIOUS STEREOTACTIC BODY RADIOTHERAPY PLANNING TECHNIQUES REPORTING SIMILAR CONTROL RATES FOR STAGE I NON-SMALL-CELL LUNG CANCER
. 72:1597-1603.
2008
A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118)
. 71:79-86.
2008
Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118
. 71:71-78.
2008
Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis
. 71:64-70.
2008
Intensity-Modulated Radiotherapy With Concurrent Chemotherapy for Previously Irradiated, Recurrent Head and Neck Cancer
. 69:1067-1073.
2007
IMRT-based 4D Stereotactic Radiotherapy for Early Stage Inoperable Lung Cancer: Initial Clinical Validation of a Radiobiologic Model
. 69:s487.
2007
Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme
. 69:831-838.
2007
Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost:: A planning study
. 69:589-597.
2007
Breathing-synchronized delivery: A potential four-dimensional tomotherapy treatment technique
. 68:1572-1578.
2007
Distribution of brain metastases in relation to the hippocampus:: Implications for neurocognitive functional preservation
. 68:971-977.
2007
Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119)
. 68:852-857.
2007
Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer
. 67:187-195.
2007
149 An Update of Phase II Results From RTOG 0211: A Phase I/II Study of Gefitinib+Radiation for Newly-Diagnosed Glioblastoma Patients
. 66:s83-s84.
2006
2886 Dynamic Delivery Quality Assurance for IMRT to Account for Target Motion
. 66:s711-s712.
2006
Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-β for supratentorial glioblastoma:: Results of RTOG 9710
. 66:818-824.
2006
Tumor volume changes on serial imaging with megavoltage CT for non-small-cell lung cancer during intensity-modulated radiotherapy:: How reliable, consistent, and meaningful is the effect?
. 66:135-141.
2006
A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023
. 65:1422-1428.
2006
Integral radiation dose to normal structures with conformal external beam radiation
. 64:962-967.
2006
Health-Related Quality of Life and Cognitive Status in Patients with Glioblastoma Multiforme Receiving Escalating Doses of Conformal Three-Dimensional Radiation on RTOG 9803
. 63:s78.
2005
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases
. 63:37-46.
2005
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma
. 63:47-55.
2005
Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: Report from the Radiation Therapy Oncology Group
. 62:318-327.
2005
Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer
. 62:104-110.
2005
The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy
. 61:779-788.
2005
The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes
. 60:1639-1644.
2004
A challenge to traditional radiation oncology
. 60:1241-1256.
2004
American Society for Therapeutic Radiology and Oncology and American College of Radiology Practice Guideline for the Performance of Stereotactic Body Radiation Therapy
. 60:1026-1032.
2004
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol
. 60:853-860.
2004
Patterns of failure in supratentorial primitive neuroectodermal tumors treated in children's cancer group study 921, a phase III combined modality study
. 60:204-213.
2004
Phase I/II conformal three-dimensional radiation therapy dose escalation study in patients with supratentorial glioblastoma multiforme: Report of the radiation therapy oncology group 98–03 protocol
. 60:s163-s164.
2004
The value of PET/CT in gross tumor volume delineation in lung and esophagus cancer
. 60:s536-s537.
2004
Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: A phase I clinical study
. 59:1107-1115.
2004
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (radiation therapy oncology group 9813): Implications for studies testing initial treatment of brain tumors
. 59:1122-1126.
2004
Breathing synchronized delivery — a new technique for radiation treatment of the targets with respiratory motion
. 57:s185-s186.
2003
CT-based analysis of free-breathing vs. maximum inspiratory breath hold techniques for 3-D conformal radiation therapy and intensity modulated radiation therapy in lung cancer: a potential basis for dose-escalation
. 57:s417.
2003
Emphasizing conformal avoidance versus target definition for IMRT planning in H&N cancer
. 57:s299-s300.
2003
FISH analysis of genetic markers of prognosis for high grade astrocyotmas using tissue micro-arrays from RTOG clinical trials
. 57:s135.
2003
Induction chemotherapy followed by standard thoracic radiotherapy vs. hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small cell lung cancer: phase III study of the eastern cooperative oncology group (ECOG 2597)
. 57:s141.
2003
Megavoltage CT imaging for adaptive helical tomotherapy of lung cancer
. 57:s429.
2003
Motexafin gadolinium (MGd) overcomes adverse survival effect of anemia in brain metastases (BM) patients treated with whole brain radiation therapy (WBRT): analysis of a phase III randomized trial
. 57:s133.
2003
Phase I results from RTOG BR-0211, a phase I/II study of an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD 1839 (Iressa), with radiation therapy in glioblastoma multiforme (GBM)
. 57:s329.
2003
Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients
. 57:s135-s136.
2003
Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma
. 57:208-216.
2003
Image guidance for precise conformal radiotherapy
. 56:89-105.
2003
Application of multimodality imaging to radiation therapy treatment planning of brain tumors
. 54:240-241.
2002
Consolidative abdomino-pelvic radiotherapy following surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer
. 54:66-67.
2002
Defining the impact of beam parameters in breath-hold tomotherapy
. 54:315-316.
2002
Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of radiation therapy oncology group (RTOG) trial BR-0018
. 54:49.
2002
LINAC-based radiosurgery in the treatment of trigeminal neuralgia: a preliminary report
. 54:303-304.
2002
Megavoltage CT images from a helical tomotherapy system
. 54:333-334.
2002
Motexafin gadolinium prolongs time to neurologic progression in lung cancer patients with brain metastases: results of a randomized phase III trial
. 54:92.
2002
Overexpression of the epidermal growth factor receptor (EGFR), as determined by EGFR immunostaining on tissue microarrays, fails to demonstrate prognostic value for patients with glioblastoma multiforme: a report from RTOG 7401, 7918, 8302, 8409, 9006, 9305, 9602, and 9806
. 54:96.
2002
Phase II trial of motexafin gadolinium (MGd, xcytrin®) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM)
. 54:246.
2002
Predictors of survival for patients with brain metastases: results of a randomized phase III trial
. 54:93.
2002
Randomized prospective comparison of stereotactic radiosurgery (SRS) followed by conventional radiotherapy (RT) with BCNU to RT with BCNU alone for selected patients with supratentorial glioblastoma multiforme (GBM): report of RTOG 93-05 protocol
. 54:94-95.
2002
The impact of a mid-treatment MRI on defining GBM boost volumes
. 54:245-246.
2002
A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases
. 53:519-526.
2002
Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: Clinical experience with and without chemotherapy
. 53:702-706.
2002
Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix
. 52:637-642.
2002
Brain metastases regress isometrically following radiation, therapy allowing the use of 1D W.H.O. RECIST criteria for adequate response evaluation
. 51:250.
2001
Gating-by-rotation: a solution to the problem of intratreatment motion in helical tomotherapy
. 51:95.
2001
Impairment of neurocognitive function in brain metastases patients: baseline results from the phase III trial with motexafin gadolinium
. 51:135-136.
2001
Most troublesome quality of life concerns in patients with brain metastases: baseline results from the phase III trial with motexafin gadolinium
. 51:410.
2001
Tumor-specific intracellular delivery of gadolinium in glioblastoma
. 51:251.
2001
Radiosurgery for patients with brain metastases: A multiinstitutional analysis, stratified by the RTOG recursive partitioning analysis method
. 51:426-434.
2001
A new approach to dose escalation in non-small-cell lung cancer
. 49:23-33.
2001
Brain tumor committee
. 51:11-18.
2001
Tumor utilization committee
. 51:103-109.
2001
RSR13 plus cranial radiation therapy improves survival in patients with brain metastases compared to the RTOG recursive partitioning analysis brain metastases database: Update of a phase II trial
. 48:203.
2000
XCYTRIN™ (motexafin gadolinium) and whole brain radiation for patients with brain metastases: Lead-in phase to randomized trial - final results
. 48:204.
2000
Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: Results of a prospective treatment protocol
. 45:657-665.
1999
Microvascular and tumor cell alterations during continuous hyperfractionated irradiation: An electron microscopic investigation on the rat R1H rhabdomyosarcoma
. 44:895-904.
1999
2082 Clinical trial of gadolinium texaphyrin (GD-TEX) in patients with brain metastases
. 45:320.
1999
2171 Patterns of failure in uterine papillary serous carcinoma (UPSC) suggest a role for whole abdomen radiation therapy (RT) and intravaginal boost
. 45:366.
1999
48 Multi-institutional survival analysis of brain metastases patients treated with radiosurgery, stratified by RTOG RPA classification
. 45:171.
1999
Comparison of methods for response analysis of central nervous system neoplasms
. 42:261.
1998
Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions
. 42:116-117.
1998
Phase IB/II trial of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) for patients with brain metastases: Final results
. 42:198.
1998
Selective uptake and retention of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) in tumors demonstrated by MRI in phase I and II clinical trials
. 42:263.
1998
Topotecan, as a radiosensitizer, for brainstem glioma (BSG) of childhood: First report of CCG 0952, a phase i study
. 42:357.
1998
Treatment of early stage epithelial ovarian cancer with chemotherapy and abdomino-pelvic radiotherapy: Results of a prospective treatment protocol
. 42:148.
1998
A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases
. 39:445-454.
1997
Pelvic exenteration for cervix cancer: Would additional intraoperative interstitial brachytherapy improve survival?
. 38:143-148.
1997
A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis
. 35:27-35.
1996
214 Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tract obstructions
. 36:142.
1996
98 A multi-institutional phase II study of hyperfractionated accelerated radiation therapy for unresectable non-small cell lung cancer: Initial report of ECOG 4593
. 36:207.
1996
RADIOSURGERY IN THE INITIAL MANAGEMENT OF MALIGNANT GLIOMAS - SURVIVAL COMPARISON WITH THE RTOG RECURSIVE PARTITIONING ANALYSIS
. 32:931-941.
1995
110 Phase II clinical trial of amifostine (WR2721), cisplatin (C), vinblastine (V) (ACV) and thoracic radiation therapy (RT) for unresectable stage III non small cell lung cancer (NSCLC).
. 32:196.
1995
8 A multi-institutional outcome and prognostic factor analysis of radiosurgery (RS) for resectable single brain metastasis
. 32:145.
1995
83 Patterns of failure in CCG 921, a phase III study of chemoradiotherapy in high-risk intracranial PNET
. 32:182.
1995
STEREOTAXIC RADIOSURGERY FOR GLIOBLASTOMA-MULTIFORME - REPORT OF A PROSPECTIVE-STUDY EVALUATING PROGNOSTIC FACTORS AND ANALYZING LONG-TERM SURVIVAL ADVANTAGE
. 30:541-549.
1994
CONSENSUS STATEMENT ON STEREOTAXIC RADIOSURGERY QUALITY IMPROVEMENT
. 28:527-530.
1994
Stereotactic radiosurgery improves survival in malignant gliomas compared with the RTOG recursive partitioning analysis
. 30:164-165.
1994
Vaginal apex recurrence in patients with early stage endometrial cancer treated by postoperative external beam rt without intravaginal boost
. 30:282.
1994
CONSENSUS GUIDELINES FOR HIGH-DOSE-RATE REMOTE BRACHYTHERAPY IN CERVICAL, ENDOMETRIAL, AND ENDOBRONCHIAL TUMORS
. 27:1241-1244.
1993
INGUINOFEMORAL RADIATION OF N0,N1 VULVAR CANCER MAY BE EQUIVALENT TO LYMPHADENECTOMY IF PROPER RADIATION TECHNIQUE IS USED
. 27:963-967.
1993
THORACIC VOLUME RADIATION SPARING FOLLOWING ENDOBRONCHIAL BRACHYTHERAPY - A QUANTITATIVE-ANALYSIS
. 25:703-707.
1993
Glioblastoma treated with external beam radiotherapy and stereotactic radiosurgery boost
. 27:152-153.
1993
DEFINING THE ROLE OF RADIOSURGERY IN THE MANAGEMENT OF BRAIN METASTASES
. 24:619-625.
1992
Is inguino-femoral irradiation as effective as lymphadenectomy for N0, N1 vulvar disease?
. 24:209.
1992
SEQUENTIAL COMPARISON OF LOW-DOSE RATE AND HYPERFRACTIONATED HIGH-DOSE RATE ENDOBRONCHIAL RADIATION FOR MALIGNANT AIRWAY OCCLUSION
. 23:133-139.
1992
Radiosurgery for brain metastases
. 21:172.
1991
Sequential comparison of ldr and hyperfractionated HDR EBRT for MAO
. 21:137-138.
1991
The role of magnetic resonance angiography in the radiosurgical management of arteriovenous malformations
. 21:196.
1991
Y-90.B72.3 AGAINST PANCREATIC-CANCER - DOSIMETRIC AND BIOLOGICAL ANALYSIS
. 19:627-631.
1990
Stereotactic radiation: Evaluation of brain tumor response
. 19:269.
1990
RADIATION-INDUCED THYROID NEOPLASMS 1920 TO 1987 - A VANISHING PROBLEM
. 16:1471-1475.
1989
An improved ray casting technique for surface-shaded display: applications in radiation treatment planning
. 17:126.
1989
Direct computerized tomographic (CT) dosimetry of endobronchial implants
. 17:239.
1989
Minimization of small bowel volume utilizing customized “Belly Board” mold
. 17:187-188.
1989
Monte Carlo and convolution dosimetry for stereotactic radiosurgery
. 17:196.
1989
Radioimmunotherapy: dosimetric and biological analysis
. 17:121.
1989
"Hope" Drives Quality of Life in Patients With Brain Metastases, But, the "Hope Center" Remains Elusive: An Analysis of NRG-CC003
2025
Signal-Seeking P2R Trial of Proton or IMRT Dose Intensification in GBM: NRG-BN001
2025
CDK 4/6 Inhibitors are Potent Radiosensitizers in Retinoblastoma Protein Positive Meningiomas
2022
Dosimetric Impact of Intrafraction Prostate Motion in DoseEscalated Linac-Based SBRT
2022
Intrafraction Prostate Motion Management during Dose-Escalated Linac-Based SBRT
2022
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424
2020
Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today
2020
Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): Initial Outcomes and RT Plan Quality Report
2019
Significant Preservation of Neurocognitive Function (NCF) and Patient-Reported Symptoms with Hippocampal Avoidance (HA) during Whole-Brain Radiotherapy (WBRT) for Brain Metastases: Final Results of Nrg Oncology CC001
2019
Tumor Treating Fields and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from NSCLC in the phase 3 METIS study
2019
Defining an Intermediate Risk Group for Low Grade Glioma? An Analysis of the National Cancer Database
2018
Dosimetric Impact of Large Displacement of the Metal Port of the Tissue Expander in Intensity Modulated Proton Therapy
2018
Survival and Prognostic Factors in Patients with Gastrointestinal Cancers and Brain Metastases
2018
Prognostic Factors in Patients with Renal Cell Carcinoma and Brain Metastases
2017
The Prognostic Value of
BRAF, C-KIT,
and
NRAS
Mutations in Melanoma Patients With Brain Metastases
2017
Low-Risk Meningioma: Initial Outcomes from NRG Oncology/RTOG 0539
2016
A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813
2016
An Independently Validated Nomogram for Individualized Estimation of Survival Among Patients With Newly Diagnosed Glioblastoma: NRG Oncology/RTOG 0525 and 0825
2016
Impact of Age on Early Volumetric Changes in Adults with Low-Grade or Benign Intracranial Neoplasms Treated With External Beam Radiation Therapy
2016
Improving Radiation Oncology Residency Structure: A Multi-Institutional Survey Study
2016
Multi-institutional Validation of a Novel Glioblastoma Prognostic Nomogram Incorporating MGMT Methylation
2016
Proton Therapy in the USA From 2012 to 2014-Increasing Treatment of Pediatric, Lung, Head and Neck, Gastrointestinal, and Breast Cancers, But No Increase in Prostate Cancer Treatments: A Study From the National Association for Proton Therapy
2016
Radiomics for Survival Analysis and Prediction in Glioblastoma (GBM)-A Preliminary Study
2016
Robust Lymph Nodes Proton Scanning Irradiation for Locally Advanced Breast Cancer
2016
Suppression of Major Histocompatibility Complex (MHC) Class I and II Mediates Resistance to Anti-PD-1 in Lung Adenocarcinoma Tumors That Can Be Overcome by Radiation Therapy
2016
The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases
2016
The Effect of Gene Mutations on Survival in Patients With Melanoma Following the Development of Brain Metastases
2016
Treatment Responses and Survival in IDH1-Mutant Grade II and III Gliomas in NRG Oncology/RTOG 9802 and 9813
2016
A Multi-institutional Analysis of Acute Toxicity After Neoadjuvant Chemoradiation Using Photons or Protons in Trimodality Esophageal Cancer Patients
2015
Bevacizumab Use in Patients With Subtotal Resection of Newly Diagnosed Glioblastoma (GBM): A Secondary Analysis of NRG Oncology/RTOG 0825
2015
Comparison of Overall Survival for Esophageal Cancer Patients Treated With Neoadjuvant Proton or Photon Chemoradiation: A Multi-institutional Analysis
2015
Cost-Effectiveness of Prophylactic Cranial Irradiation With Hippocampal Avoidance in Limited Stage Small Cell Lung Cancer
2015
Fact or Fiction: Proton Beam Therapy is Primarily for Patients With Prostate Cancer
2015
Intermediate-Risk Meningioma: Initial Outcomes from NRG Oncology/RTOG-0539
2015
Is Pencil Beam Scanning Dosimetrically Advantageous Compared to Passively Scattered Proton Therapy for Unresectable Pancreatic Cancer?
2015
Minimal Early Increase in Contrast Enhancement After Chemoradiation Therapy for Glioblastoma Predicts Worse Overall and Progression Free Survival
2015
NRG Oncology/RTOG 0525 Role of Machine Learning Analytic Tools for Survival Prediction of GBM Patients Using Clinical Parameters
2015
Novel Proton Beam Arrangements for Prostate Cancer Using In Vivo Range Verification May Significantly Reduce the Risk of High Grade Rectal Toxicities
2015
Radiation Modality Use and the Incidence of Postoperative Complications and Length of Hospitalization After Trimodality Therapy for Esophageal Cancer: A Multi-institutional Analysis
2015
The Effect of Gene Mutations on Survival in Patients With Adenocarcinoma of the Lung Following the Development of Brain Metastases
2015
Treatment Recommendations for Elderly Patients With Newly Diagnosed Glioblastoma Lack Worldwide Consensus
2015
Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA)
2014
An Evaluation of Multi-Institutional Data-Transfer to Facilitate Personalized Computational Modeling
2014
Application of a Survival-Predicting Nomogram Based Primarily on Whole-Brain Radiation Therapy-Treated Patients With Brain Metastases Yields Significant Underestimates for Radiosurgery-Treated Patients
2014
Breath-Hold Intensity Modulated Proton Therapy (BH-IMPT) for Lung SBRT: Feasibility Study
2014
Comparison of Coronary Vessel Contouring Using Non-Contrast Cardiac Gated CT Versus CT Angiogram
2014
Factors Predicting for Increase in Peritumoral Edema Following Radiosurgery of Brain Metastases
2014
Is Prophylactic Cranial Irradiation (PCI) With Hippocampal Avoidance (HA) Justified in Limited-Stage Small Cell Lung Cancer (LS-SCLC)?
2014
Large Tumor Size Increases the Risk of Developing Symptomatic Pleural Effusions Following Stereotactic Body Radiation Therapy for Lung Cancer
2014
Mature Survival Data from RTOG 9802: A Phase III Study of Radiation Therapy (RT) With or Without Procarbazine, CCNU, and Vincristine (PCV) for Adult Patients with High-Risk Low-Grade Glioma (LGG)
2014
An Evaluation of Worldwide Proton Beam Therapy Clinical Trials
2013
Cilengitide Inhibits Proliferation and Shows Combined Effects With Radiation in Breast Cancer Cell Lines
2013
Credentialing in Hippodampal (HC) Sparing Techniques for RTOG 0933: Quality Assurance (QA) Report
2013
Feasibility Study Testing the Incorporation of Resting State fMRI Data in Radiation Therapy Planning to Limit Dose to Cognitive Function Networks in Patients With Primary Brain Tumors
2013
Predictive Factors for Brain Metastases and Relapse and Prognostic Factors for Survival in Stage III-IV Non-Small Cell Lung Cancer (NSCLC)
2013
Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole Brain Radiation Therapy (WBRT) Versus WBRT Plus Stereotactic Radiosurgery (SRS) in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA)
2013
Time to Intracranial Failure Following Postresection Cavity Radiosurgery for Patients With a Single Intracranial Metastasis
2013
A Revised RTOG Recursive Partitioning Analysis (RPA) Model for Gliobtastoma Based Upon Multiplatform Biomarker Profiles
2012
IDH Status Predicts Benefit From PCV With Radiation Therapy in Anaplastic Oligodendroglioma (RTOG 9402)
2012
Memantine for the Prevention of Cognitive Dysfunction in Patients Receiving Whole-brain Radiation Therapy (WBRT): First Report of RTOG 0614, a Placebo-controlled, Double-blind, Randomized Trial
2012
Phase I Safety and Pharmacokinetic (PK) Study of Veliparib in Combination With Whole Brain Radiation Therapy (WBRT) in Patients (pts) With Brain Metastases
2012
Sublobar Resection With Intraoperative 125I Brachytherapy Versus Stereotactic Body Radiation Therapy for Treatment of Clinical Early-Stage Non-small Cell Lung Cancer in Patients not Eligible for Lobectomy
2012
The Effect of Tumor Subtype on the Time From Primary Diagnosis to Development of Brain Metastases and Survival in Women With Breast Cancer
2012
Validation of the Breast Cancer-specific Graded Prognostic Assessment (GPA) for Patients With Breast Cancer With Brain Metastases
2012
Phase II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma (GBM): Results of RTOG 0513
2011
Pre-Treatment Mean Standardized Uptake Value (SUV) of Non-small Cell Lung Cancer (NSCLC) is Associated with Subsequent Development of Brain Metastases
2011
Predicting Neurocognitive Function (NCF) Impairment following Fractionated Stereotactic Radiotherapy (FSRT) for Benign or Low-Grade Adult Brain Tumors
2011
Predictive Value of Tumor Recurrence Using Urinary Vascular Endothelial Growth Factor Levels in Patients Receiving Radiation Therapy for Glioblastoma
2011
RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM)
2011
SEER Database Analysis of Survival Impact of Early Adjuvant Radiotherapy (EART) for Resected Supratentorial Low-grade Glioma (SLGG) in Adults
2011
A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database
2008
A randomized trial or chemotherapy plus radiotherapy (RT) versus RT alone for anaplastic oligodendroglioma (RTOG 9402): The perspective of longer follow-up
2008
An update on correlative molecular Endpoints from RTOG 0211: Phase I/II study of gefitinib plus radiation for newly diagnosed glioblastoma patients
2008
Prognostic factors for complete obliteration of arteriovenous malformations treated with LINAC-based stereotactic radiosurgery
2008
The prognostic value of nestin expression in newly diagnosed GBM: Report from the RTOG
2008
Adaptive tomotherapy planning for integrated boost doses in rapidly responding lung cancers
2007
Dosimetric evaluation of helical IMRT, traditional IMRT and 3-D conformal radiation for inoperable non-small cell lung cancer
2007
Early upregulation of peripheral benzodiazepine receptor expression by radiation-induced damage to mouse lung in vivo
2007
Neurocognitive impact of whole brain radiation on patients with brain metastases: Secondary analysis of RTOG BR-0018
2007
Age as an independent prognostic factor in patients with glioblastoma: A radiation therapy oncology group analysis
2006
Methods to address cancer disparities in special populations
2006
Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a randomized phase 3 trial
2006
Motexafin gadolinium-based treatment planning MRI identifies occult brain metastases amenable to stereotactic radiosurgery: Imaging results of a phase II trial of motexafin gadolinium and whole brain radiotherapy with stereotactic radiosurgery
2006
Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: Results of Radiation Therapy Oncology Group trial br-0018
2004
The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: A review of preclinical and correlative clinical data
2004
Phase I/II conformal three-dimensional radiation therapy dose escalation study in patients with supratentorial glioblastoma multiforme: Report of the radiation therapy oncology group 98-03 protocol
2004
Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: Report of ECOG study 4593
2001
The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: A phase III study in a high-risk patient population
1997
Continuous 28 day iododeoxyuridine (IUdR) infusion and hyperfractionated accelerated radiotherapy (HART) for malignant glioma: A phase I clinical and thymidine replacement study.
1997
Endobronchial and endoesophageal high dose rate brachytherapy for malignant airway and digestive tact obstructions
1997
Experience with the functional assessment of cancer therapy lung (FACT-L) in ECOG 4593, a Phase II hyperfractionated accelerated radiation therapy (HART) trial.
1997
Feasibility & acute toxicities of craniospinal hyperfractionated radiotherapy (CHFRT) for high risk intracranial primitive neuroectodermal tumors (HRPNET); CCG-9931; A groupwide Phase II study of intensive chemotherapy (CT) & CHFRT
1997
Optic nerve tolerance to single and fractionated radiation simulating radiosurgery: A rabbit model using visual evoked potentials, fundoscopy and histology
1997
CORRELATION OF POST-RADIOSURGICAL HISTOPATHOLOGY WITH RADIOGRAPHIC CHANGES
1993
GLIOBLASTOMA TREATED WITH EXTERNAL-BEAM RADIOTHERAPY AND STEREOTAXIC RADIOSURGERY BOOST
1993
Elective Target Coverage for Pancreatic Cancer: When Less Does Not Clearly Achieve More
2022
The Evolving Personalized Landscape of Colorectal Cancer Therapies
2021
Untitled Reply
2026
In Reply to Halperin
2024
Radiation Target Volumes for Glioblastoma
2024
The Complexity of Managing Large Brain Metastasis
2019
The Case for Proton Beam Therapy
2018
Self-Referral in Radiation Oncology: Has Caveat Emptor Replaced Primum Non Nocere? Reply
2012
RESPONSE TO "DIAGNOSIS-SPECIFIC PROGNOSTIC FACTORS, INDEXES, AND TREATMENT OUTCOMES FOR PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES: A MULTI-INSTITUTIONAL ANALYSIS OF 4,259 PATIENTS." (INT J RADIAT ONCOL BIOL PHYS 2010:77:655-661) REPLY
2011
HIPPOCAMPAL-SPARING WHOLE-BRAIN RADIOTHERAPY: A "HOW-TO" TECHNIQUE USING HELICAL TOMOTHERAPY AND LINEAR ACCELERATOR-BASED INTENSITY-MODULATED RADIOTHERAPY: IN REGARD TO GONDI V, ET AL. (INT J RADIAT ONCOL BIOL PHYS 2010;78:1244-1252) RESPONSE
2011
TREATMENT-RELATED PNEUMONITIS AND ACUTE ESOPHAGITIS IN NON-SMALL-CELL LUNG CANCER PATIENTS TREATED WITH CHEMOTHERAPY AND HELICAL TOMOTHERAPY: IN REGARD TO SONG ET AL.
2010
COMMISSIONING AND QUALITY ASSURANCE OF RAPIDARC RADIOTHERAPY DELIVERY SYSTEM: IN REGARD TO LING ET AL. (INT J RADIAT ONCOL BIOL PHYS 2008;72;575-581): ABSENCE OF DATA DOES NOT CONSTITUTE PROOF; THE PROOF IS IN TASTING THE PUDDING
2009
VALIDATION OF GRADED PROGNOSTIC ASSESSMENT INDEX FOR PATIENTS WITH BRAIN METASTASES: IN REGARD TO SPERDUTO ET AL. (INT J RADIAT ONCOL BIOL PHYS 2008;70:510-514) IN REPLY TO DRS. NIEDER AND MOLLS
2008
In regard to Sperduto et al. (Int J Radiat Oncol Biol Phys 2008;70 : 510-514) - In reply to Drs. Weltman and Brandt
2008
Integral radiation dose to normal structures with conformal external beam radiation:: In regards to Aoyama et al. (Int J Radiat Oncol Biol Phys 2006;64:962-967) -: In response to Dr. Penagaricano
2006
Helical tomotherapy as a means of administering total or partial scalp irradiation:: In regards to Bedford
et al
. (
Int J Radiat Oncol Biol Phys
2005;62:1549-1558)
2006
In regard to Dr. Souhami et al.
2005
In regard to Dr. Souhami et al. - In reply to Dr. Kondziolka et al.
2005
Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme: Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of radiation therapy oncology group 93-05 protocol: In regard to Souhami et al. (Int J Radiat Oncol Biol Phys 2004; 60 : 853-860) - Response
2005
Lack of survival benefit after stereotactic radiosurgery boost for glioblastoma multiforme:: Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme:: Report of radiation therapy oncology group 93-05 protocol:: In regard to Souhami
et al
. (
Int J Radiat Oncol Biol Phys
2004;: 60:853-860)
2005
Accelerated hypofractionation
2005
What is the appropriate primary end point for clinical trials for patients with brain metastases? In response to Drs. Burri and Asher
2002
Retrospective vs. randomized data: The prevalence of bias. In response to Drs. Millar and Laperriere
2002
Manpower issues and training program directions in radiation oncology
1996
GLIOBLASTOMA-MULTIFORME - WHO SHOULD RECEIVE STEREOTAXIC BOOST THERAPY
1994
GROIN NODE IRRADIATION FOR VULVAR CANCER - TREATMENT PLANNING MUST DO MORE THAN SCRATCH THE SURFACE - REPLY
1993
ENDOBRONCHIAL BRACHYTHERAPY - WITHER PRESCRIPTION POINT
1992
ENDOBRONCHIAL IRRADIATION - IS HDR BETTER
1990
CURRENT RADIOSURGERY PRACTICE - RESULTS OF AN ASTRO SURVEY
1994
TREATMENT OF ARTERIOVENOUS-MALFORMATIONS WITH STEREOTAXIC RADIOSURGERY EMPLOYING BOTH MAGNETIC-RESONANCE ANGIOGRAPHY AND STANDARD ANGIOGRAPHY AS A DATABASE
1993
A 3-DIMENSIONAL VOLUME VISUALIZATION PACKAGE APPLIED TO STEREOTAXIC RADIOSURGERY TREATMENT PLANNING
1991
EARLY CHANGES IN TUMOR METABOLISM AFTER TREATMENT - THE EFFECTS OF STEREOTAXIC RADIOTHERAPY
1991
MONTE-CARLO AND CONVOLUTION DOSIMETRY FOR STEREOTAXIC RADIOSURGERY
1990
MINIMIZATION OF SMALL-BOWEL VOLUME WITHIN TREATMENT FIELDS UTILIZING CUSTOMIZED BELLY BOARDS
1990
ENDOBRONCHIAL IRRADIATION FOR MALIGNANT AIRWAY-OBSTRUCTION
1989
Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee
2017
Improving Outcomes for Esophageal Cancer using Proton Beam Therapy
2016
Comparative Evaluation of Tile Estimation Workflows for STaRT Pre-Planning in Patients with Recurrent Brain Metastasis
2025
Decoding Auto-Segmentation: A Deep Qualitative Analysis of Commercial Tools for Organs-at-Risk Delineation
2025
Dose-Escalated Intensity Modulated Proton Therapy (IMPT) for Node-Positive Prostate Cancer-First Report of Clinical Outcomes
2025
Normal Tissue Complication Probability Model Predicting the Risk of Radiation Necrosis after Stereotactic Radiosurgery for Small Brain Metastases
2025
Plan Quality Reporting of the Phase II Stereotactic MR-Guided Adaptive Radiation Therapy in One Fraction (SMART ONE) Trial
2025
Timing and Predictors of Grade 3 Lymphopenia in Lung Cancer Patients Undergoing Proton Chemoradiotherapy
2025
Erratum to: Gondi V, Deshmukh S, Brown PD, et al. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. Int J Radiat Oncol Biol Phys. 2023;117:571-580. (International Journal of Radiation Oncology, Biology, Physics (2023) 117(3) (571–580), (S0360301623004388), (10.1016/j.ijrobp.2023.04.030))
2025
Ablative Stereotactic MR-Guided Adaptive Radiotherapy in Patients with Infra -Diaphragmatic Oligometastatic Disease
2024
Clinical Endpoints Correlation with Molecular Features in the NRG Oncology/RTOG 9802 Low-Grade Glioma, Low-Risk Observation Arm
2024
Contrast-Enhancing Lesions Induced by CNS-Directed Intensity Modulated Proton Therapy: Distribution Patterns, Kinetics and Clinical Outcomes
2024
Development of a Machine Learning-Based Tool to Predict Local Failure after Stereotactic Radiosurgery for Small Brain Metastases
2024
Evaluating Neurocognitive Recovery Following Stereotactic Radiosurgery and Whole Brain Radiation Therapy: Insights from a Pooled Analysis of Three Phase Ill Trials
2024
Impact of Systemic Therapy Selection on Brain Metastasis Outcomes in Lung Cancer Patients Treated with Stereotactic Radiosurgery
2024
Phase 2 Trial of Stereotactic MR-Guided Adaptive Radiation Therapy in One Fraction (SMART ONE)
2024
Primary Endpoint Results of NRG CC003: Phase IIR/111 Trial of Prophylactic Cranial Irradiation (PCI) with or without Hippocampal Avoidance (HA) for Small Cell Lung Cancer (SCLC)
2023
A Comparison of Local Failure and Necrosis Following Different Radiosurgery Strategies for Large Brain Metastases
2023
Characterization of Large Brain Metastases with
18
F-Fluciclovine PET/CT Treated with Staged Stereotactic Radiosurgery (SSRS): Phase 1 Proof-of-Concept Interim Analysis
2023
Comparing Changes in Medicare Reimbursement for Radiation Oncology and Medical Oncology (2010-2020)
2023
Integration of an App-Based Cognitive Evaluation Program into Radiosurgery Practice: Outcomes and Patient Survey Analysis from a Prospective Observational Study
2023
Stereotactic Radiosurgery for Small Intact Brain Metastasis: A Comparative Evaluation of 3 Different Single Fraction Prescription Doses
2023
Modern Meningioma Methods: Molecular Diagnostics and High Dose Protons
2023
Modern Meningioma Methods: Molecular Diagnostics and High Dose Protons
2023
Does hippocampal atrophy correlate with patient-reported adaptive function one year following radiotherapy? Results from a prospective trial
2022
An Optimal Solution Study on a Non-Invasive Stereotactic Radiosurgery Instrument Optimizer for Stereotactic Radiosurgery of Single Brain Metastasis
2022
Changes Over Time for Radiation Oncology Reimbursement for Specific Treatment Courses
2022
Dedicated Isotropic 3-D T1 SPACE Sequence Imaging for Radiosurgery Planning Improves Brain Metastases Detection and Reduces the Risk of Intracranial Relapse
2022
Does Hippocampal Atrophy Correlate with Neurocognitive Outcomes One Year Following Radiotherapy? Results from a Prospective Trial
2022
Evaluating Accuracy, Completion Time and Usability of Everyday Touch Devices for Contouring
2022
Evaluating Heterogeneity of Hippocampal Avoidant Whole Brain Radiotherapy (HA-WBRT) Treatment Effect on Neurocognitive Function (NCF): Secondary Analysis of NRG-CC001
2022
Evaluating the Utility of EQ5D-5L in Patients with Brain Metastases: Secondary Analysis of NRG-CC001
2022
Evaluation of Pulsed Reduced Dose Rate (PRDR) Intensity Modulated Proton Therapy (IMPT) for Re-Irradiation of CNS Malignancies
2022
Feasibility and Initial Results of a Daily Wearable Patient-Tracking Device for Optimization of Radiation Machine Utilization and Timely Treatment Delivery
2022
Longitudinal Assessment of Gross Tumor Volume in Abdominal and Pelvic Patients Undergoing MR-Guided Online Adaptive Radiotherapy as a Predictive Biomarker of Treatment Response
2022
Management of Cardiac Implantable Electronic Devices for Patients Receiving MR-Guided Radiotherapy: 4-Year Single Institution Experience
2022
Pulsed Reduced Dose Rate (PRDR) Intensity Modulated Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results
2022
The Impact of Thyroid Gland Volume on the Risk of Developing Post-RT Hypothyroidism in Breast Cancer Patients Requiring Comprehensive Nodal Irradiation
2022
68
Ga-DOTATATE PET: The Future of Meningioma Treatment
2022
Association Between Glycosyltransferase Expression and Survival in Head and Neck Cancer
2022
Change in Hippocampus Volume as a Function of Radiation Dose: Early Results From a Prospective Trial with Standardized Imaging and Morphometric Evaluation
2021
Circadian Factors Impact Survival From Brain Metastases for Patients Treated With Whole Brain Radiation
2021
Cumulative Target Volume Dose and Locoregional Failure in Pancreatic Cancer Patients With Treated With Ablative Stereotactic MR-Guided Adaptive Radiation Therapy (SMART)
2021
Enhancing Enrollment of Patients to Radiation Oncology Clinical Trials Across a Multi-Institutional Community-Academic Partnership: An Interrupted Time Series Analysis
2021
Establishing the Aortic Maximum Tolerated Dose (MTD) for Ablative 5-Fraction Stereotactic MR-Guided Adaptive Radiation Therapy (SMART)
2021
Evaluation of a Prospective Radiation Oncology Departmental Peer Review Process using Standardized Simulation Directives
2021
ITV-Negation and Dose Fall-Off Features Result in OAR Dosimetric Superiority Favoring MR-Guided Radiotherapy (MRgRT), and Intensity Modulated Proton Therapy (IMPT) Over Volumetric Modulated Arc Therapy (VMAT) for Treatment of Distal Esophageal Cancer
2021
Impact of Breath-Hold MR-Guided Radiotherapy (MRgRT(BH)) vs. Free-Breathing CT Image-Guided Radiotherapy (CT-IGRT(FB)) on Gastrointestinal Sparing and Dose Conformality in Adrenal SBRT
2021
Impact of Dose Calculation Algorithm on Skin Dose for Breast Cancer Treated With Intensity Modulated Proton Therapy
2021
Impact of Time Interval Between Diagnostic and Planning MRI on Tumor Volume and Anatomic Displacement for Brain Metastases Undergoing Stereotactic Radiosurgery
2021
Indications for Plan Adaptation in Patients with Adrenal Metastases Treated With Stereotactic MR-Guided Adaptive Radiation Therapy (SMART)
2021
Long-Term Multi-Institutional Outcomes of 5-Fraction Ablative Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) for Inoperable Pancreas Cancer With Median Prescribed Biologically Effective Dose of 100 Gy
10
2021
MR-Guided Radiotherapy (MRgRT) for Laryngeal Cancer With Real-Time Visualization of Intrafraction Larynx Motion
2021
Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (SMART) With Median Biologically Effective Dose of 100 Gy10 for Oligometastases
2021
Patterns of Care in Stereotactic Body Radiation Therapy Fractionation Schedules in Non-Small Cell Lung Cancer in the United States From 2004-2016
2021
Patterns of Utilization and Clinical Adoption of 0.35 MR-Guided Radiation Therapy in the United States-Understanding the Transition to Adaptive, Ultra-Hypofractionated Treatments
2021
A Novel Pre-plan Technique for On-table Adaptation of Pancreatic Stereotactic MR-guided Online Adaptive Radiotherapy
2020
Assessment of Intrafraction Cervico-Uterine Motion in the Definitive Treatment of Locally Advanced Cervical Cancer Using MR-Guided Radiotherapy
2020
Comparison of Cardiopulmonary Sparing and Dose Conformality in Distal Esophageal Cancer: Intensity Modulated Proton Therapy (IMPT), MR-guided Radiotherapy (MRgRT), and Volumetric Modulated Arc Therapy (VMAT)
2020
Evaluation of Photon and Proton Radiotherapy Plan Quality With the Knowledge-Based Approach in NRG BN001 Clinical Trial
2020
Favorable Initial Outcomes of Abdominopelvic Reirradiation Using Dose-Escalated Magnetic Resonance Image-Guided Radiation Therapy
2020
Multi-Institutional Experience of Proton Beam Radiotherapy for Pediatric Ependymomas
2020
NRG Oncology/RTOG 1119: PHASE II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery with Concurrent Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer - A Collaborative Study of NRG and KROG (NCT01622868)
2020
Radiotherapy (RT) Dose-intensification (DI) Using Intensity-modulated RT (IMRT) versus Standard-dose (SD) RT with Temozolomide (TMZ) in Newly Diagnosed Glioblastoma (GBM): Preliminary Results of NRG Oncology BN001
2020
Safety of Proton Therapy for Patients With Primary Central Nervous System Germinoma and Non-Germinomatous Germ Cell Tumors: Report from a Multi-Institutional Database Analysis
2020
Steep Dose-response Relationship between Maximum Hippocampal Dose and Memory Deficits following Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT) for Brain Metastases: A Secondary Analysis of NRG/RTOG 0933
2020
Stereotactic Body Radiotherapy of Painful Osseous Metastases: A Correlation Meta-Analysis
2020
Survival Impact Of Postoperative Radiotherapy Timing In Pediatric And Young Adult Ependymoma
2020
The Use of Adjuvant Radiotherapy and Chemotherapy in Low Grade Glioma Patients in the United States from 2010-2016
2020
A Prospective Multi-Institutional Study of Clinical Outcomes for Meningioma Patients Treated with Proton Beam Radiotherapy
2019
Comprehensive Prognostic and Predictive Molecular Subgroup Analysis within the High-risk Treatment Arms of NRG Oncology/RTOG 9802: a Phase III Trial of RT versus RT plus PCV in High-risk Low-grade Gliomas
2019
Preservation of Neurocognitive Function (NCF) with Conformal Avoidance of the Hippocampus during Whole-Brain Radiotherapy (HA-WBRT) for Brain Metastases: Preliminary Results of Phase III Trial NRG Oncology CC001
2018
Consensus Radiation Therapy Contouring Guidelines for Glioblastoma, Based on NRG Recommendations
2018
Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma
2018
Association between Increase in WBC Absolute Value and Survival Before, During, and After Concurrent Chemoradiation Therapy in Patients With Newly Diagnosed Glioblastoma
2017
Correlation Between Inflammatory Markers and Outcome in Patients With Newly Diagnosed Glioblastoma
2017
Mean Glucose During Chemoradiation for Glioblastoma is an Independent Prognostic Factor
2017
Clinical Outcomes of Patients with Stage II-III Non-Small Cell Lung Cancer (NSCLC) Treated with Proton Beam Therapy (PBT) on the Proton Collaborative Group (PCG) Prospective Registry Trial
2016
Interobserver Variability in Atlas-Based, Manual Segmentation of the Hippocampus in Patients With Brain Metastases
2016
Low Levels of Acute Toxicity Associated With Proton Therapy for Low-Grade Glioma: A Proton Collaborative Group Study
2016
Lymph-Vascular Space Invasion as a Risk Factor for Local Recurrence in Endometrial Adenocarcinoma Stratified by Surgical Technique
2016
Clinical Outcomes for Esophageal Cancer Patients Treated With Intensity Modulated Radiation Therapy Compared to 3-D Conformal Radiation Therapy: An Analysis of the National Cancer Data Base
2015
Prognostic Models for Patients With Brain Metastases Treated With Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy
2015
Volumetric Analysis of the Hippocampus in Long Term (similar to 1 year) Survivors of Whole Brain-Radiation Therapy for Brain Metastasis
2015
Dose Escalation for GBM in the Temozolamide Era
2015
Real-Time Pretreatment Review Limits Unacceptable Deviations: Quality Assurance (QA) Results of RTOG 0933
2014
A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT & SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320
2013
Ataxia Telangiectasia Mutated (ATM) Gene Variants in American Indians
2010
Interim Results of a Phase I Risk-Stratified Dose Escalation Study using Hypofractionated Helical Tomotherapy for Non-small Cell Lung Cancer
2010
Estimated Risk of Perihippocampal Disease Progression after Hippocampal Avoidance during Whole-brain Radiotherapy: Comprehensive Multi-institution Review of 371 Patients with 1133 Brain Metastases
2009
Rib Fracture Incidence after Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer: Latency and Dose-response
2009
A multi-institutional validation study of a new prognostic index (Graded prognostic assessment, GPA) for patients with brain Metastases
2008
Primary histology is associated with volumetric response following whole brain radiation therapy (WBRT) in patients with brain metastases (BM)
2008
A prospective study comparing CT-Based to PET/CT-based radiation treatment planning
2007
Can MVCT be used for adaptive radiotherapy? A feasibility study
2007
Image-guided, intensity-modulated hypofractionated radiotherapy for inoperable non-small cell lung cancer: Preliminary results of a phase I dose escalation study
2007
Single institution experience treating 100 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery
2007
Whole brain radiation therapy with hippocampal avoidance and simultaneously integrated brain metastases boost with helical tomotherapy: A planning study
2007
MRI response after whole brain radiation therapy in patients with brain metastases and its association with change in neurocognitive function
2006
Ocular sparing using image-guided helical tomotherapy (IGHT) in spontaneous sino-nasal tumors in dogs
2006
A challenge to traditional radiation oncology (vol 60, pg 1241, 2004)
2005
Erratum: A challenge to traditional radiation oncology (International Journal of Radiation Oncology Biology (2004) 60 (1241-1256))
2005
Erratum: Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): Implications for studies testing initial treatment of brain tumors (International Journal of Radiation Oncology Biology Physics (2004) 59 (1122-1126))
2005
Phase I study pilot arms of radiotherapy and Carmustine with temozolomide for anaplastic astrocytoma (Radiation therapy oncology group 9813): Implications for studies testing initial treatment of brain tumors. (vol 59, pg 1122, 2004)
2005
Integral radiation dose to normal structures with conformal external beam radiation
2005
The value of PET/CT in gross tumor volume delineation in lung and esophagus cancer
2004
CAVERNOUS SINUS CRANIAL NEUROPATHIES - IS THERE A DOSE-RESPONSE RELATIONSHIP FOLLOWING RADIOSURGERY
1993
Identifiers
International Standard Serial Number (ISSN)
0360-3016
Electronic International Standard Serial Number (EISSN)
1879-355X
